688238 logo

Obio Technology (Shanghai) XSSC:688238 Stock Report

Last Price

CN¥4.22

Market Cap

CN¥2.7b

7D

-7.9%

1Y

-62.3%

Updated

29 Jul, 2024

Data

Company Financials +

Obio Technology (Shanghai) Corp., Ltd.

XSSC:688238 Stock Report

Market Cap: CN¥2.7b

688238 Stock Overview

A biotechnology company, focuses on the development of gene therapy vectors in China.

688238 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Obio Technology (Shanghai) Corp., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Obio Technology (Shanghai)
Historical stock prices
Current Share PriceCN¥4.22
52 Week HighCN¥12.32
52 Week LowCN¥4.12
Beta0.40
11 Month Change-8.86%
3 Month Change-31.60%
1 Year Change-62.32%
33 Year Changen/a
5 Year Changen/a
Change since IPO-67.54%

Recent News & Updates

Recent updates

Shareholder Returns

688238CN Life SciencesCN Market
7D-7.9%-1.4%-2.8%
1Y-62.3%-39.5%-21.0%

Return vs Industry: 688238 underperformed the CN Life Sciences industry which returned -39.5% over the past year.

Return vs Market: 688238 underperformed the CN Market which returned -21% over the past year.

Price Volatility

Is 688238's price volatile compared to industry and market?
688238 volatility
688238 Average Weekly Movement7.5%
Life Sciences Industry Average Movement6.0%
Market Average Movement5.8%
10% most volatile stocks in CN Market9.0%
10% least volatile stocks in CN Market3.9%

Stable Share Price: 688238's share price has been volatile over the past 3 months.

Volatility Over Time: 688238's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
2013731Guodong Jiawww.obiosh.com

Obio Technology (Shanghai) Corp., Ltd., a biotechnology company, focuses on the development of gene therapy vectors in China. The company provides gene function and gene therapy research, and other CRO services, such as drug target and drug efficacy research. It also offers CDMO services, such as process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production for the research and development of genetic drugs.

Obio Technology (Shanghai) Corp., Ltd. Fundamentals Summary

How do Obio Technology (Shanghai)'s earnings and revenue compare to its market cap?
688238 fundamental statistics
Market capCN¥2.73b
Earnings (TTM)-CN¥138.37m
Revenue (TTM)CN¥233.59m

11.7x

P/S Ratio

-19.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688238 income statement (TTM)
RevenueCN¥233.59m
Cost of RevenueCN¥256.67m
Gross Profit-CN¥23.09m
Other ExpensesCN¥115.28m
Earnings-CN¥138.37m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 29, 2024

Earnings per share (EPS)-0.21
Gross Margin-9.88%
Net Profit Margin-59.23%
Debt/Equity Ratio11.1%

How did 688238 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.